D. Cella, M. Michaelson, A. Bushmakin, J. Cappelleri, C. Charbonneau, S. Kim, Jim Z. Li, R. Motzer
{"title":"3002转移性肾癌(mRCC)患者舒尼替尼与干扰素- α作为一线治疗的最终生活质量(QOL)结果和地理分析","authors":"D. Cella, M. Michaelson, A. Bushmakin, J. Cappelleri, C. Charbonneau, S. Kim, Jim Z. Li, R. Motzer","doi":"10.1016/S1359-6349(09)70601-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":207270,"journal":{"name":"European Journal of Cancer Supplements","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)\",\"authors\":\"D. Cella, M. Michaelson, A. Bushmakin, J. Cappelleri, C. Charbonneau, S. Kim, Jim Z. Li, R. Motzer\",\"doi\":\"10.1016/S1359-6349(09)70601-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":207270,\"journal\":{\"name\":\"European Journal of Cancer Supplements\",\"volume\":\"57 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/S1359-6349(09)70601-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S1359-6349(09)70601-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)